32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts

Table 1 (abstract O38). See text for description

	Intermediate/poor risk
	N+I	S	N+I PD-L1 <1%	S PD-L1 <1%	N+I PD-L1 ≥1%	S PD-L1 ≥1%
	N=425	N=422	N=284 (74%)^a	N=278 (71%)^a	N=100 (26%)^a	N=114 (29%)^a
ORR per IRRC, n (%) [95% CI]	177 (42) [37-47]	112 (27) [22-31]	106 (37) [32-43]	79 (28) [23-34]	58 (58) [48-68]	25 (22) [15-31]
	P<0.0001		Odds ratio (95% CI)=1.50 (1.04-2.17)^b		Odds ratio (95% CI)=4.92 (2.61-9.34)^b
Median PFS per IRRC, months (95% CI)	11.6 (8.7-15.5)	8.4 (7.0-10.8)	11.0 (8.1-14.9)	10.4 (7.5-13.8)	22.8 (9.4-NR)	5.9 (4.4-7.1)
HR (CI)	0.82 (99.1% CI, 0.64-1.05)		1.00 (95% CI, 0.80-1.26)		0.46 (95% CI, 0.31-0.67)
	P=0.0331		P=0.9672^b		P<0.0001^b
Median OS, months (95% CI)	NR (28.2-NE)	26.0 (22.1-NE)	NE (28.2-NE)	NE (24.0-NE)	NE	19.6 (14.8-NE)
HR (CI)	0.63 (99.8% CI, 0.44-0.89)		0.73 (95% CI, 0.56-0.96)		0.45 (95% CI, 0.29-0.71)
	P<0.0001		P=0.0249^b		P=0.0006^b

^aPercentage based on number of PD-L1 evaluable patients. ^bExploratory unstratified analysis. NE, not estimable